Fempro 2.5 mg is a non-steroid selective third-generation aromatase inhibitor. The structure and activity of this drug is similar to anastrazole, and is appointed for the same reasons. Male bodybuilders and other athletes have found their own benefit in the use of letrozole, thanks to its ability to mitigate / eliminate estrogenic side effects associated with the use of aromatizing anabolic-androgenic steroids, such as:
- increase in body fat
- fluid retention, etc.
Letrozole is one of the latest achievements in the field of struggle with the directed inhibition of aromatase. In clinical studies, doses of 0.1 mg and 0.5 mg resulted in a decrease in estrogen levels by 75% and 78%, respectively, in many patients.